

INDEX

A

- ACD. *See* Acid-citrate-dextrose (ACD)
- Acid-citrate-dextrose (ACD) 27, 88, 92
- Adenosine deaminase (ADA).....26
- Adipose tissue.....48, 54
- Agarose gel (2%)..... 77–79, 104–108,
121, 124, 126, 127, 131, 190, 204, 213, 220–222,
224–226, 262
- Agarose gel electrophoresis..... 77–79, 104–108,
121, 126, 190, 204
- Alcian blue..... 49, 51, 56, 58
- Alizarin red..... 49, 51, 56–58
- Allelic polymorphism146, 147
- Allogeneic.....24, 159, 160, 209, 212,
239, 246, 248, 271, 273, 275, 294
stem cell transplant (allo-SCT) 209, 271,
273, 275
- AML1-ETO188, 193
- Amnis imaging cytometry41
- Amplificor mycobacterium tuberculosis
(MTB) test251
- Amplification refractory mutation system
(ARMS).....77
- Amplified mycobacterium tuberculosis
test (AMTD)..... 251, 252, 260
- Anesthesia17, 19
coelenterazine17
- Antibody.....26, 27, 31, 38, 59, 102,
115, 139, 167, 173, 174, 176, 179
- Aspergillosis239, 245–247, 257, 263
- Autologous24, 28, 163, 168,
239, 273–275, 277

B

- B22026, 172
- BAL. *See* Bronchoalveolar lavage (BAL)
- B cells25, 26, 28–31, 33–35,
37, 41, 43, 66, 140, 164, 177, 178, 181, 210, 217,
218, 231, 275, 276
- Bcl-1
Bcl-1/IgH MTC nested PCR.....225–226
Bcl-1/IgH rearrangement.....225

Bcl-2

- Bcl-2/IgH rearrangement Q-PCR.....222–223
- Bcl-2 MBR, MCR nested PCR.....224–225
- Bcr-Abl31, 188, 192–193, 210
- Biodistribution 8, 9, 19
- Bioluminescence 5–9, 14, 17–19
- Biophotonic imaging1
- Biotin..... 61, 76, 89
- Bone marrow
inflammatory cell.....179
stem cell..... 12–15, 24, 25
- Bone marrow transplantation 13, 17, 24
Mice 13, 17
- Bronchoalveolar lavage (BAL)..... 38, 241, 245,
257, 258, 261, 263, 264
- Buffers
HEPES13, 15
NLB+SDS Buffer.....89, 92
Nuclear Lysis Buffer (NLB)89
Red Cell Lysis Buffer (RCLB)89
TBE..... 104, 111, 260, 280

C

- Calcium-modulating cyclophilin ligand
interactor (TACI)26
- Candida*
C. albicans..... 240
C. glabrata..... 239, 240
C. krusei 240
- Candidiasis239
- Capillary electrophoresis..... 106, 110, 111,
276, 281–285, 288, 293–304
CE-MS coupling.....298
- CBF β -MYH11188, 195–196, 205
- CD227, 28, 31, 33, 35–37, 172
- CD3 24–28, 31–33, 35–37, 39, 140,
163, 165, 171, 172, 174, 175, 177–181, 273, 274
- CD424–28, 33–37, 39, 161,
164–172, 174, 177–179, 181, 273–275
- CD527–31, 33–35, 37, 172
- CD727, 28, 31–33, 35–37
- CD824–28, 31–33, 35–37, 39,
116, 165–167, 171, 172, 174, 178, 179, 273–275

CD10	27, 28, 30, 31, 33–35, 41–43, 164, 174, 178
CD13	27–29
CD14	27, 28, 33, 36–38, 48, 172, 174, 177, 274
CD15	27, 37, 274
CD16	24, 27, 28, 31–33, 39, 140, 163, 172, 174, 177, 181
CD19	24–35, 37, 39, 42, 43, 48, 118, 131, 133, 164, 172, 174, 177, 178, 181, 273, 275, 276
CD20	26–28, 31, 33–35, 41–43, 172
CD22	28
CD23	27–29, 31, 33–35
CD27	26, 164, 171, 174, 178
CD33	27–29, 37
CD34	24, 25, 27–30, 33, 36, 41, 48, 66, 67, 70, 162–164, 174, 178, 180, 275, 276
CD38	31, 33, 37, 41, 67, 164, 174, 178, 181
CD45	24–29, 31, 33, 35, 37, 39, 41–43, 48, 167, 174, 175, 177–180
CD48	66
CD56	24, 27, 28, 31, 32, 140, 163, 172, 174, 177, 181, 273, 274
CD64	27–29, 37
CD71	27, 39
CD73	48
CD89	142
CD90	48
CD94	140, 150
CD103.....	28, 30, 32
CD105.....	48
CD117.....	27, 29
CD133.....	67, 70, 174, 178
CD138.....	28, 35, 37, 217, 233, 234
CD150.....	66
CD158.....	154, 157
CD294.....	37
CD79a.....	28, 34
CD11b/CD11c	27
CD49b/CD49f.....	67
CD49d	37
CD45RA.....	26, 67, 165, 166, 174, 178
CDR2 /CDR3	221
Cetyl Trimethyl Ammonium Bromide (CTAB), Chimerism	
calculation of chimerism.....	287
detection.....	272–276, 281–285
donor type	274
lineage specific.....	271–289
peaks.....	284, 286–288
problems	
encountered problems.....	284
extra signals	288
Chondrogenic lineage differentiation	56
Chromosome 19q13,4	142
c-kit.....	66
Clonotypic sequence.....	210, 219–220
Cobblestone area-forming cell/Long-term culture	
initiating cells (CAFC/LTC-IC).....	69, 70
Collagenase	50, 54, 61
Colony forming units (CFU) assay	
CFU GEMM.....	69
CFU GM.....	69
Colony stimulating factor	24
Common myeloid progenitors.....	66
Common variable immune	
deficiency (CVID).....	25, 26
Complementarity determining	
region (CDR)	218, 234
Contamination	76, 97, 121, 134, 179, 205, 210, 216, 219, 220, 223, 225, 226, 234, 235, 242, 243, 245, 249, 250, 255, 259–261, 263, 264, 288
CpG islands.....	148
Crystal violet	51, 57
C type lectin receptors.....	140
Culture	10, 12, 16, 17, 19, 48–50, 53–58, 60, 61, 65, 67–70, 171, 172, 178, 243, 245–247, 249, 253, 254, 259, 264, 294
CXCR-4.....	24, 67
CyTOF mass cytometry.....	40
D	
DAP 12	141
Data analysis	
censoring	298–299
stratification and confounding.....	150
Digoxigenin-CSPD.....	87
Dimethylsulfoxide (DMSO)	50, 55, 235
Disease free survival (DFS)	211
Dithiothreitol (DTT).....	280
DLI. <i>See</i> Donor lymphocyte infusions (DLI)	
DNA	
Isolation (extraction).....	36, 88, 89, 91–93, 117, 121, 190, 204, 212, 217, 232, 241, 243, 247, 257–259, 261–263, 279–281, 283, 285, 286
J	218, 221
preparation.....	91
purification	247, 260
from nails.....	279, 282
sequencing	79
Donor lymphocyte infusions (DLI).....	171, 187, 211, 274

Donors..... 14, 24, 47, 48, 73, 76,
82–84, 88, 101, 116, 128, 134, 150–153, 160,
162–164, 170, 172, 187, 211, 212, 271–277, 279,
283–285, 287, 289, 166, 167
unrelated..... 83, 84, 152, 289

E

EDTA. *See* Ethylenediaminetetraacetic acid (EDTA)
Engraftment..... 2–4, 68, 101, 161–163, 271
Ethidium Bromide (EtBr)..... 77, 104, 107, 108,
111, 213, 220, 222, 224–226, 231, 260, 262
Ethylenediaminetetraacetic acid
(EDTA)..... 27, 50, 51, 54–56, 59,
69, 70, 88, 89, 92, 104, 117, 120, 191, 213, 232,
233, 258–260, 264
European Organization for Research and Treatment
of Cancer/Invasive Fungal Infections
Cooperative Group (EORTC)..... 240
Exons
Exon 2,3..... 75, 79, 87, 102
Exonuclease..... 77, 117, 127

F

Fas..... 140
Fast red..... 51, 58
Ferritin..... 6, 7
Fetal bovin serum (FBS)..... 13, 50, 51, 53, 54,
59, 69, 70, 173, 191
Fetal Calf Serum (FCS)..... 13, 15, 40
Fibroblasts..... 23, 47, 48
Flow cytometry..... 15, 17, 23–43, 53,
59, 70, 159–181
FLT3 gene-length mutations..... 188
Fluconazole (FLCZ)..... 240
Fluorescence activated cell sorting (FACS)..... 66, 188
Fluorescence resonance energy transfer
(FRET)..... 128, 130, 189, 242, 253
Fluorochrome..... 38–41, 128, 174,
179, 227, 265
5-Fluorouracil (5-FU, 5FU)..... 12, 19, 67
Follicular lymphoma (FL)..... 28, 34, 209–211,
218, 222, 278, 281, 282
Formamide..... 235, 281, 284
Fungi..... 241–246, 257, 258, 261
Fusarium..... 240
Fusion..... 10, 31, 76, 80, 145,
188, 189, 205, 226

G

Galactomannan..... 245, 246, 263
GAPDH..... 197, 205, 227, 229, 230
Gemstone probability state model..... 24, 37
Gene expression..... 9, 10, 60
Gene therapies..... 47

GenoM™ 6 Robotic Workstation..... 89
Genoprep B350 cartridge..... 88, 91, 254
Glycosaminoglycans..... 58
Graft
autologous graft contamination..... 168
chimerism..... 271–274, 276
graft *versus* host disease (GvHD)..... 115, 116,
150, 152, 160–166, 168, 170–173, 187, 294
graft *versus* leukemia (GvL)..... 152, 160–162,
164, 165, 172, 173, 187, 276
graft *versus* tumor (GvT)..... 115, 116
rejection..... 116, 271–274, 276
rejection detection..... 272
Granulocyte colony stimulating factor (c)..... 24
Green fluorescent protein (GFP)..... 6, 9
Group specific primers..... 87, 105, 106
Growth factors
Flt-3L..... 13
IL-3..... 12, 15
IL-6..... 13, 15, 17
SCF..... 13, 15, 17
TPO..... 13, 17
Guanidinium hydrochloride (Gu HCl)..... 259

H

Haploidentical..... 150, 151, 163, 289
HSCT..... 150, 151, 163
Haplotypes..... 82, 142–147, 152
Hematopathology..... 24
Hematopoiesis..... 1–19, 24, 65, 66
Hematopoietic malignancies..... 24, 27–43, 116,
159, 209, 294
Hematopoietic stem cells (HSC)
activation..... 12
differentiation..... 12
human..... 12, 13, 16, 17, 65–67
isolation..... 66, 67, 70
labelling..... 7–10, 12
murine..... 2, 14–15
purification..... 66
quiescence..... 65
self renewal capacity..... 65, 66, 68
transduction
lentiviral..... 10–13, 16–17
retroviral..... 10–15
in vivo imaging..... 1, 2, 7, 10
Hematopoietic stem cell transplantation
(HSCT)..... 23, 73–84, 139–153,
187–206, 239–265, 294
Hematoxylin-cosin..... 57
Histocompatibility
major (MHC)..... 73
minor h antigens
autosomal..... 118
Y-chromosome..... 120

Human Leukocyte Antigens (HLA)
 extended typing82
 genes.....73, 74, 77, 79, 80, 103
 HLA-A 74–76, 82–84, 87,
 89, 90, 92, 101–106, 108, 111, 149, 167
 HLA-B.....74, 102, 103, 106, 108, 149
 HLA-Bw4,-Bw6.....149
 HLA-C74, 82, 84, 102, 103,
 106, 108, 148, 149, 152
 HLA class 1.....74, 79, 102, 105,
 141, 142, 146–151
 HLA-DPB174, 83
 HLA-DQA1.....74, 118
 HLA-DQB174, 83, 105, 106, 108
 HLA-DR27–29, 48, 87, 174, 178
 HLA-DRB1.....74, 75, 78, 79,
 83, 101, 103, 119
 HLA-E150
 HLA-G149
 typing methods
 PCR-RFLP120
 PCR-SBT.....75, 84
 PCR-SSO.....75–77, 79, 84, 87–98
 PCR-SSP75, 77–79, 84,
 91, 145, 146
 typing resolution
 high.....82
 intermediate.....76
 low82
 medium.....84
 Hyphae.....243

I

IFN- γ 140, 167
 Ig D26, 164
 Ig M26, 164
 Imaging
 bioluminescence (BLI)5, 14
 computed tomography.....4, 5
 fluorescence imaging (Fim)5
 positron emission tomography (PET)4, 5
 single photon emission (SPECT).....4
 Immunoglobulin heavy chain (IgH).....210–212,
 214, 215, 218–223, 225, 227, 228,
 230, 231, 234, 235
 Immunoreceptor Tyrosine-based Inhibitory Motifs
 (ITIM).....141
 Immunosuppression24–26, 248
 In situ hybridization (ISH)
 chromogenic ISH (CISH),
 fluorescence ISH (FISH)188, 212
 Internal transcribed spacers (ITS)51, 255
 International histocompatibility working group
 (IHWG).....145, 146

Invasive fungal infections (IFIs)239–265
 Irradiation.....13, 17, 19, 161
 IS986250
 IS1245255
 IS 6110249, 252, 258–260, 262, 265
 Isoamylalcohol.....280
 Isolation.....47–62, 88, 89, 91, 92,
 97, 117, 120, 121, 167, 170, 190–192, 204, 212,
 216–217, 232, 233, 245, 246, 259, 284–286
 Isolation of cells by flow sorting281
 lineage specific chimerism272, 274–276

K

65 kDa protein249
 Killer cell
 immunoglobulin like receptors
 (KIRs).....140, 141, 143,
 147–149, 151, 152
 inhibitory receptors.....140
 lectin like receptor (KLR).....140
 leukocyte immunoglobulin like
 receptor (LIR).....140
 polymorphisms139–153

L

Lentroviral transduction10–12, 16–17
 Leukemia
 acute lymphoblastic leukemia (ALL).....28, 30,
 33, 150–152, 188, 230, 231
 acute myeloid leukaemia (AML).....27–29,
 33, 150–152, 188, 191, 193, 194, 196, 205, 206
 chronic lymphocytic leukemia (CLL).....28, 29,
 31, 34, 35, 210, 211, 217, 231, 234
 chronic myelogenous leukemia (CML)31, 33,
 117, 188, 210
 myeloid lymphoid leukemia (MLL)188, 203, 206
 Leukocyte Immunoglobulin like receptors
 (LILR)140, 142
 Leukocyte receptor complex (LRC).....142
 Leukocyte subsets.....272–275, 277
 Lin.....66, 172, 178, 181
 Lineage markers
 B220172
 CD4.....24, 27,
 33, 35, 37, 39, 164, 166–168, 170, 172, 174,
 177–179, 181, 273, 275
 CD8.....24, 27, 31, 33, 35, 37,
 167, 172, 174, 178, 179, 273, 275
 CD11b.....27
 c-Kit66
 Mac1,
 Sca-1.....66
 Ter119,
 Line probe assays (LIPA)76, 253

Lipofectamine 12, 14, 18
 Long terminal repeat (LTR).....11
 Loop mediated isothermal amplification
 (LAMP) 252, 264
 Luciferase
 click beetle (*Pyrophorus lagiothalam*)8
 firefly (*Photinus pyralis*).....8
 Renilla reniformis..... 8
 Luciferin.....6, 9, 14, 17–19, 80
 Luminex technology..... 87–98, 247
 Lymphoid malignancies212
 Lymphoid progenitors.....66
 Lymphoma26–28, 31, 33–36, 159,
 209, 210, 212, 218, 222, 223, 227

M

Magnetic resonance imaging (MRI)4–7
 Mass spectrometry.....40, 244, 245, 293–304
 Matrix-assisted laser desorption ionization-time
 of flight (MALDI-TOF) 145, 245
 Median Fluorescent Intensity (MFI) 96, 97, 180
 Medium
 Dulbecco's modified Eagle's medium
 (DMEM)..... 13, 15, 49–51, 54
 Hank's balanced salt solution (HBSS)
 methylcellulose culture medium68
 Myelocult H510013
 Opti-MEM 1 12, 14
 StemSpan SFEM 13, 15, 19
 Melting curve analysis 128–130, 242
 Mercaptoethanol 13, 69, 259
 Mesenchymal stem cells47–61
 Microarray
 hybridization.....241, 244
 normalization.....299
 technology52–53, 60–61, 241, 247
 Microsatellites 273, 276, 277,
 284, 286–289
 Minimal residual disease (MRD)
 lymphoid disorders209–235
 myeloid disorders.....187–206
 Minimum inhibitory concentration (MIC).....247
 Molecular imaging.....10
 Mononuclear cell.....31, 53, 61, 121,
 168, 212, 216, 228, 232
 isolation212, 216–217
 Multi drug resistance (MDR) 253, 254, 256, 257
 Mycobacteria239–265
 Mycobacterium tuberculosis complex
 (MTC).....225–226, 240, 247–256, 258

N

N-acetyl L-cysteine (NALC) / NaOH.....259
 National Marrow Donor Program (NMDP)83

Natural killer (NK) cells 24, 25, 66,
 139–153, 163–164, 177, 273–275
 receptors 139–153
 Niche 24, 31, 47, 65
 Nitrocellulose membrane strips76
 Non-hodgkin lymphoma.....26, 33
 Nontuberculous mycobacteria (NTM) 240, 248–250,
 255, 256, 258, 264
 Nucleic acid amplification tests
 (NAATs) 241, 245–247,
 249–253, 255–257, 259, 260, 264, 265
 Nucleic acid sequence-based amplification
 (NASBA).....243

O

Oil red 49, 51, 56, 58–59
 Oligonucleotide
 coated polystyrene microspheres.....76
 primers.....76, 77, 79, 87–98,
 125, 127, 129, 132, 135, 190, 191
 Osteogenic lineage differentiation55–56

P

Panfungal.....241, 247
 Paraffin
 embedded tissue.....232
 section.....232
 Paroxysmal nocturnal hemoglobinuria.....36–38
 Paroxysmal nocturnal hemoglobinuria
 (PNH)36–38
 PCR-Sequence Specific Oligoprobe
 (PCR-SSO) 75–77, 79, 84,
 87–98, 145, 146
 Penicillin-streptomycin.....50, 51, 53, 54, 69
 Phenol chloroform..... 232, 233, 258,
 259, 279, 280, 282, 283
 Phenotype232, 233, 258, 259,
 279, 280, 282, 283
 Phosphate-buffered saline (PBS) 12–16, 50,
 51, 53, 54, 56–59, 70, 117, 173, 212, 259, 262, 283
 Phosphatidyl inositol glycan A (PIGA)36
 Photoacoustic tomography (PAT)10
 Plasmids 11–13, 16, 189,
 204, 205, 213, 234
 Plasticity48
 PML-RARA 188, 196–197, 205
 Polyacrylamide gel
 preparation.....220
 Polymerase Chain Reaction (PCR)
 allele specific 120–127, 135, 211
 amplification.....79, 89–90, 92–94, 97,
 121, 126–128, 130, 131, 134, 218, 220–226,
 229, 231, 234, 235, 243, 244, 250, 251, 257,
 276, 277, 289

Polymerase Chain Reaction (PCR) (*cont.*)
 asymmetric 93, 94, 97, 282
 multiplex nested qualitative RT-PCR.....203–204
 nested PCR 203, 219, 221,
 223–226, 234, 235, 242, 254, 265
 Polymerase Chain Reaction-Sequence Specific Primer
 (PCR-SSP).....75, 77–79, 84, 91, 145, 146
 Polymorphism73–76, 79, 80, 102,
 103, 124, 126, 127, 130, 131, 134, 139–153, 276
 Polymyxin B19
 Primers52, 75, 87, 102, 117,
 145, 190, 210, 242, 278
 Probability state model24, 37
 Probe 6–8, 10, 52, 60, 61, 75–77,
 79, 88–90, 94, 96–98, 121, 127–130, 146, 189,
 191–199, 202, 205, 206, 210, 216, 227–230, 235,
 241–244, 252, 253, 261
 Protease283, 302
 Proteinase K 89, 233, 280
 Proteomics.....293–304
 Pyrosequencing..... 80, 146, 244, 255

R

Reduced intensity conditioning (RIC) 161, 162,
 166, 170, 172, 212, 271, 273
 Relapse 31, 150–152, 160,
 163–165, 172, 173, 187, 188, 210–212, 274–276
 Repopulation68
 Reporter genes.....1–19
 Resonance energy transfer
 (FRET).....128, 130, 189, 242, 253
 Restriction enzyme digestion124
 Retroviral transduction 11–15
 Reverse transcriptase PCR
 PCR-RFLP120, 124–126, 135, 255
 PCR-SBT.....75, 84
 qualitative PCR188, 210, 213–215,
 217–226
 real time PCR.....52, 60, 79, 117,
 120, 127–129, 135, 188, 189, 191–206, 210, 216,
 226, 229, 233, 235, 243, 250, 253–255, 261, 276
 reference strand confirmation analysis
 (RSCA)..... 120, 130, 135
 short tandem repeat PCR (STR-PCR) 277, 279,
 281–284
 single stranded confirmation polymorphism
 (SSCPs)126
 Reverse transcription 61, 190,
 193–198, 202, 204, 232
 Reverse transcription polymerase chain reaction
 (RT-PCR) 145, 188–206, 210
 Rituxan26
 RNA
 aRNA61
 isolation 52, 59, 121, 190–192, 204, 232

mRNA..... 145, 171, 189, 204, 205, 210, 243
 RNeasy 190–192
 16s rRNA 249, 251, 252, 255
 18s rRNA 241, 258
 28S rRNA.....241

S

Salting out89, 92
 SCID. *See* Severe combined immunodeficiency (SCID)
 SCID cell repopulating assay (SRC)68
 SDA. *See* Strand displacement amplification (SDA)
 SDS. *See* Sodium dodecyl sulfate (SDS)
 Semi-quantitative PCR.....210
 Sequence based typing (PCR-SBT)..... 75, 79–80, 84
 Sequencing43, 74, 79–82, 84,
 101–112, 131, 134, 146, 215, 216, 220–221, 231,
 241, 244, 255, 294, 296, 302
 Serum9, 12–14, 16, 19, 50,
 53–55, 121, 128, 164, 173, 191, 245, 257, 263,
 293, 304
 Severe combined immunodeficiency (SCID)..... 12, 26
 Short tandem repeats (STR)273, 276–277, 279,
 282, 285, 289
 Single nucleotide polymorphism (SNP)..... 74, 134,
 146, 276
 Single-Stranded Conformation (SSC) 25, 177, 178
 SNP. *See* Single nucleotide polymorphism (SNP)
 Sodium dodecyl sulfate (SDS)..... 89, 92,
 104, 259, 280, 295, 297, 304
 Software19, 37–41, 77, 80,
 91, 96, 97, 103, 105, 106, 111, 112, 131, 190, 201,
 221, 228–230, 234, 284, 287, 295, 298
 Spoligotyping255
 STR. *See* Short tandem repeats (STR)
 Strand displacement amplification (SDA).....251–252
 Streptavidin-PE88
 Substrate.....6–9, 14, 17–19, 55, 77
 SYBR Green 205, 235, 242

T

Taqman52, 60, 117, 189,
 191, 198, 199, 202, 205, 216, 227, 228, 230, 243
 T-cells
 cytotoxic T lymphocytes (CTL) 163, 172
 helper 164–165, 274
 memory T-cells116
 suppressor273–275
 Terminators81, 104–106, 117, 215
 The GeneXpert MTB/RIF test..... 253–255, 257
 The Killer-cell Immunoglobulin-like Receptor (KIR)
 database147
 expression 148, 150
 genotyping..... 145–146, 151, 152
 KIR2DL1141, 143, 144, 148, 149
 KIR2DL2 141–143, 148

KIR2DL3 141–143, 148
 KIR2DL4 141, 143, 148, 149
 KIR3DL1 141–143, 146, 147, 149
 KIR3DL2 141, 143, 147, 149
 KIR3DL3 141, 143, 147–149
 KIR2DL5A 141
 KIR2DL5B 142
 KIR2DP1 141, 143, 144
 KIR3DP1 141, 143, 145
 KIR2DS1 141, 143, 149, 152
 KIR2DS2 141, 143, 149
 KIR2DS3 141, 143, 144, 149
 KIR2DS4 141, 143, 145, 149
 KIR2DS5 141, 143, 144, 149
 KIR3DS1 141–143, 149, 152
 ligands 141, 148–150, 152
 The National Institute of Allergy and Infectious Diseases
 Mycoses Study Group (MSG) 240
 TRAIL 140

Transcription 61, 190, 193–198, 202, 204, 232
 Transduction 10–17
 Transfection 10–14, 16, 18
 reagents
 lipofectamine 12, 14
 Transferrin 6, 7
 Transgenesis 10, 11
 Tween 20 233

U

Unambiguous HLA typing 103
 Universal sample processing (USP) 259, 262, 264
 Uracil-N-glycosylase (UNG) 191, 193, 194,
 197–199, 202, 205, 243, 260

Z

Zygomycetes 239, 240